{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T04:01:18Z","timestamp":1746849678066,"version":"3.40.5"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.critrevonc.2025.104678","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T21:19:40Z","timestamp":1741468780000},"page":"104678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The role of radium-223 in the evolving treatment landscape of metastatic castration-resistant prostate cancer: A narrative review"],"prefix":"10.1016","volume":"210","author":[{"given":"\u00c1lvaro","family":"Pinto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"G\u00f3mez-Iturriaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejo","family":"Rodriguez-Vida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Antonio","family":"Vallejo-Casas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104678_bib1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.LBA18","article-title":"Final overall survival (OS) with talazoparib (TALA) +\u2009enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial","volume":"43","author":"Agarwal","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104678_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1385466","article-title":"Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer","volume":"14","author":"Anido-Herranz","year":"2024","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib4","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib5","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/ijc.32851","article-title":"A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population","volume":"147","author":"Badrising","year":"2020","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104678_bib6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41391-021-00412-6","article-title":"Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223","volume":"25","author":"Badrising","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2025.104678_bib7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in Metastatic Prostate Cancer before Chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib8","first-page":"1","article-title":"LBA71 - Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON study)","volume":"35","author":"Brighi","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib9","doi-asserted-by":"crossref","first-page":"6250s","DOI":"10.1158\/1078-0432.CCR-06-0841","article-title":"High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?","volume":"12","author":"Bruland","year":"2006","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104678_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100761","article-title":"Cross-resistance and drug sequence in prostate cancer","volume":"56","author":"Buck","year":"2021","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.critrevonc.2025.104678_bib11","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.220157","article-title":"A review of theranostics: perspectives on emerging approaches and clinical advancements","volume":"5","author":"Burkett","year":"2023","journal-title":"Radio. Imaging Cancer"},{"key":"10.1016\/j.critrevonc.2025.104678_bib12","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","article-title":"Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer","volume":"41","author":"Buttigliero","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.104678_bib13","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib16","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib17","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib18","doi-asserted-by":"crossref","first-page":"S1326","DOI":"10.1016\/j.annonc.2023.10.087","volume":"34","author":"Chi","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib19","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.critrevonc.2025.104678_bib20","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib21","article-title":"EAU - EANM - ESTRO - ESUR - ISUP","author":"Cornford","year":"2024","journal-title":"SIOG Guidel. Prostate Cancer"},{"key":"10.1016\/j.critrevonc.2025.104678_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib23","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib24","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"361","author":"de Bono","year":"2011","journal-title":"NEJM"},{"key":"10.1016\/j.critrevonc.2025.104678_bib25","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib26","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104678_bib27","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib28","unstructured":"European Medicines Agency (EMA) 2018. Xofigo Referral. \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/xofigo\u3009. (accessed 16 December 2024)."},{"key":"10.1016\/j.critrevonc.2025.104678_bib29","unstructured":"European Medicines Agency (EMA) 2019. Lynparza (olaparib), SmPC. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynparza-epar-product-information_en.pdf\u3009. (accessed 16 December 2024)."},{"key":"10.1016\/j.critrevonc.2025.104678_bib30","unstructured":"European Medicines Agency (EMA) 2022. Pluvicto (lutetium Lu 177 vipivotide tetraxetan) SmPC. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pluvicto-epar-product-information_en.pdf\u3009. (accessed 16 December 2024)."},{"key":"10.1016\/j.critrevonc.2025.104678_bib31","unstructured":"European Medicines Agency (EMA) 2024a. Akeega (niraparib plus abiraterone acetate) SmPC. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/akeega-epar-product-information_en.pdf\u3009. (accessed 16 December 2024)."},{"key":"10.1016\/j.critrevonc.2025.104678_bib32","unstructured":"European Medicines Agency (EMA) 2024b. Talzenna (talazoparib) SmPC. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/talzenna-epar-product-information_en.pdf\u3009. (accessed 16 December 2024)."},{"key":"10.1016\/j.critrevonc.2025.104678_bib33","unstructured":"European Medicines Agency (EMA) 2024c. Xofigo (radium Ra 223 dichloride) SmPC. \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xofigo#product-info\u3009. (accessed 16 December 2024)."},{"key":"10.1016\/j.critrevonc.2025.104678_bib34","unstructured":"FDA) 2019. Xofigo (radium Ra 223 dichloride) Prescribing information. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/203971s016lbl.pdf\u3009. (accessed 16 December 2024)."},{"key":"10.1016\/j.critrevonc.2025.104678_bib35","unstructured":"FDA) 2020a. Lynparza (olaparib) Prescribing information. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208558s014lbl.pdf\u3009. (accessed 16 December 2024)."},{"key":"10.1016\/j.critrevonc.2025.104678_bib36","unstructured":"FDA) 2020b. Rubraca (rucaparib) Prescribing information. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209115s004lbl.pdf\u3009. (accessed 16 December 2024)."},{"key":"10.1016\/j.critrevonc.2025.104678_bib37","unstructured":"FDA) 2022. Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Prescribing information. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215833s000lbl.pdf\u3009. (accessed 16 December 2024)."},{"key":"10.1016\/j.critrevonc.2025.104678_bib38","unstructured":"FDA) 2023a Akeega (niraparib and abiraterone acetate) Prescribing information. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216793s000lbl.pdf\u3009 (accessed 16 December 2024)."},{"key":"10.1016\/j.critrevonc.2025.104678_bib39","unstructured":"FDA) 2023b. Talzenna (talazoparib) Prescribing information. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/211651s010lbl.pdf\u3009. (accessed 16 December 2024)."},{"key":"10.1016\/j.critrevonc.2025.104678_bib40","doi-asserted-by":"crossref","first-page":"TPS5093","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5093","article-title":"Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study","volume":"39","author":"Fizazi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib41","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00d72 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104678_bib42","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib43","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Eng. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib44","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ctrv.2017.04.008","article-title":"Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer","volume":"57","author":"Galletti","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.104678_bib46","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41391-021-00488-0","article-title":"Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)","volume":"25","author":"George","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2025.104678_bib47","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2307","volume":"35","author":"Gillessen","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2024.11.027","article-title":"Decrease in fracture rate with mandatory bone-protecting agents in the EORTC 1333\/PEACE-3 trial comparing radium-223 combined with enzalutamide versus enzalutamide alone: a safety analysis","author":"Gillessen","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib49","first-page":"252","article-title":"Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice","volume":"44","author":"Henriksen","year":"2003","journal-title":"J. Nucl. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib50","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/cncr.35221","article-title":"Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE)","volume":"130","author":"Higano","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104678_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101993","article-title":"Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer","volume":"60","author":"Higano","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2025.104678_bib52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib53","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104678_bib54","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/ijc.35040","article-title":"Real-world safety and effectiveness of radium-223 in patients with metastatic castration-resistant prostate cancer: interim analyses of the prospective, observational RAPIT study","volume":"155","author":"Huang","year":"2024","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104678_bib55","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib56","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib57","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib58","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104678_bib59","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","article-title":"Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study","volume":"17","author":"Kantoff","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib60","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Eng. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib61","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib62","article-title":"AlphaBet: combination of radium-223 and [(17) (7)Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)","volume":"9","author":"Kostos","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.critrevonc.2025.104678_bib63","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2217\/fon-2020-0039","article-title":"Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer","volume":"16","author":"Kuppen","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib64","first-page":"1346","article-title":"Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer","volume":"10","author":"Liepe","year":"2009","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.critrevonc.2025.104678_bib65","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.21037\/tau-20-1341","article-title":"Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer-a narrative review","volume":"10","author":"Maurice Dror","year":"2021","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib66","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41391-020-00271-7","article-title":"Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center","volume":"24","author":"McKay","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2025.104678_bib67","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104678_bib68","doi-asserted-by":"crossref","first-page":"TPS5091","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5091","article-title":"A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA","volume":"39","author":"Morris","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib69","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death","volume":"71","author":"Na","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib70","unstructured":"National Comprehensice Cancer Network (NCCN) 2024. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Prostate Cancer Version 4.2024 \u2014 May 17, 2024. \u3008https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=\u20091459\u3009. (accessed 16 December 2024)."},{"key":"10.1016\/j.critrevonc.2025.104678_bib71","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/annonc\/mdw065","article-title":"Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study","volume":"27","author":"Nilsson","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib72","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semradonc.2020.07.004","article-title":"The role of theranostics in prostate cancer","volume":"31","author":"O'Dwyer","year":"2021","journal-title":"Semin Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib73","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.2967\/jnumed.123.265557","article-title":"Pain outcomes in patients with metastatic castration-resistant prostate cancer treated with (223)Ra: PARABO, a prospective, noninterventional study","volume":"64","author":"Palmedo","year":"2023","journal-title":"J. Nucl. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib74","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib75","article-title":"Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial","author":"Parker","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib76","article-title":"Mechanisms of resistance to second-generation antiandrogen therapy for prostate cancer: actual knowledge and perspectives","author":"Pinto","year":"2022","journal-title":"Med Sci. (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104678_bib77","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib78","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","author":"Saad","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib80","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2019.37.7_suppl.180","article-title":"A retrospective analysis of treatment patterns in metastatic castration-resistant prostate cancer patients treated with radium-223","volume":"37","author":"Sartor","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib81","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib82","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib83","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1634\/theoncologist.2017-0413","article-title":"Radium-223 safety, efficacy, and concurrent use with abiraterone or enzalutamide: first U.S. experience from an expanded access program","volume":"23","author":"Sartor","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2025.104678_bib84","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104678_bib85","first-page":"347","article-title":"BELFIGO \u2013 a retrospective observational study to evaluate the treatment patterns of mCRPC patients in Belgium treated with radium-223","volume":"14","author":"Seront","year":"2020","journal-title":"Belg. J. Med Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib86","doi-asserted-by":"crossref","first-page":"TPS182","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS182","article-title":"A phase I\/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress","volume":"39","author":"Shaya","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib87","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.7150\/thno.38882","article-title":"Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer","volume":"10","author":"Shen","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2025.104678_bib88","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41391-020-0236-0","article-title":"Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone\/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer","volume":"23","author":"Shore","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2025.104678_bib89","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib90","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Eng. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib91","doi-asserted-by":"crossref","first-page":"viii723","DOI":"10.1093\/annonc\/mdy424.035","volume":"29","author":"Smith","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib92","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib93","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib94","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1158\/1078-0432.CCR-16-2955","article-title":"Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models","volume":"23","author":"Suominen","year":"2017","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104678_bib95","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib96","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104678_bib97","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib98","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11523-022-00899-6","article-title":"Pattern of clinical progression until metastatic castration-resistant prostate cancer: an epidemiological study from the european prostate cancer registry","volume":"17","author":"Verry","year":"2022","journal-title":"Target Oncol."},{"key":"10.1016\/j.critrevonc.2025.104678_bib99","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1158\/1535-7163.MCT-20-0015","article-title":"Cross-resistance among next-generation antiandrogen drugs through the AKR1C3\/AR-V7 axis in advanced prostate cancer","volume":"19","author":"Zhao","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.104678_bib100","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/07357907.2019.1670203","article-title":"Increased risk of hypertension with enzalutamide in prostate cancer: a meta-analysis","volume":"37","author":"Zhu","year":"2019","journal-title":"Cancer Invest"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T05:05:32Z","timestamp":1746767132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825000666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":100,"alternative-id":["S1040842825000666"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104678","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of radium-223 in the evolving treatment landscape of metastatic castration-resistant prostate cancer: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104678"}}